terms of observable characteristics such as age, gender, and comorbidities (pϽ0.001). Samples were balanced with nearest neighbor matching. Then segmented time-series models were applied. There was a significant association between the onset of intervention and the level of utilization of these drugs. CONCLUSIONS: To isolate the effects of guidelines, we need to control for three different factors: 1) baseline differences between the two groups; 2) stepwise differences at the intervention point; and 3) trend differences after the intervention. We showed that propensity score matching can be used for the first factor, and the latter two can be controlled with the interrupted time-series model.
OBJECTIVES:
The increasing popularity of Complementary and Alternative Medicine (CAM) leading to an increasing interest of CAM assessment through pharmacoeconomic evaluation. The attempts, however, have been unsatisfactory. This study attempted to survey expert practitioners in China of TCM (Traditional Chinese Medicine) which is a major part of CAM to elucidate critical issues when assessing cost-effectiveness of TCM, and to ascertain influencing factors of measuring HR-QOL in TCM. METHODS: A questionnaire (with 20 close and open-end questions) was distributed to TCM practitioners who had been working in the field for at least 5 years and had published at least one related paper in the last 5 years. The questions were divided into two modules with module 1 about the issues of pharmacoeconomic of TCM, and module two about the influencing factors of measuring HR-QOL in TCM. Correlation and Partial Correlate test using age and professional field as control variable were used to module 1 and 2 respectively, nonrelated factors were excluded. Principal Component Analysis (PCA) was performed for remaining items. RESULTS: Of 429 questionnaires issued, 137 were recovered from 31 medical and research institutions of 8 provinces and cities in China giving a recovered rate 31.93%. Module 1 and 2 all passed the KMO and Bartlett's test of sphericity test (kmo module 1 ϭ0.56, kmo module 2 ϭ0.66). Module 1 extracted 4 common factors after the Rotation Factor Analysis with cumulative variance of 69.9%, while Moduel 2 extracted 3 with cumulative variance of 70.6%. CONCLUSIONS: The common factors from Module 1 prompted us to pay attention to during the pharmacoeconomic evaluation: patient preference; long-term outcomes; the alternative of TCM; and the overall economic burden of patients.The common factors from Module 2 required us to note during the HR-QOL research: Acceptance level of the measurement scale by patients and physicians; disease complexity; and whether HR-QOL scale reflects the characteristics of TCM.
PRM5 A REVIEW AND CLASSIFICATION OF CONTINGENT VALUATION METHOD STUDIES IN SUB-SAHARA AFRICA
Kangethe AW, Franic D University of Georgia, Athens, GA, USA OBJECTIVES: The primary objective is a review, classification and critical appraisal of contingent valuation method (CVM) healthcare studies conducted in Sub-Sahara Africa based on criteria by O'Brien and Gafni (1996) . The secondary objective is to determine the impact of the Bamako Initiative adopted in the early 1990s on CVM studies in the same setting. METHODS: CVM African healthcare studies (willingness to pay (WTP) and willingness to accept (WTA)), were identified using a comprehensive literature search in EconoLit, Google Scholar, Medline, PubMed and Web of Science between 1981 to 2010. CVM studies evaluated included WTP and WTA studies reporting primary data were included for evaluation. Primary assessment of the studies was based on the conceptual framework for evaluation of contingent valuation of healthcare programs (5 Items) (O'Brien and Gafni 1996) . Secondary assessment was based on the time horizon of publication: pre-, during-(1990s), or post-BI, and area of intervention. RESULTS: Twenty-four CVM studies were evaluated: all used WTP and compensating variation. Elicitation techniques were dominated by bidding game (42%), followed by dichotomous choice (33%), and then payment card and the open ended formats (12.5%). Majority of studies (83%) were published after 2000, the remainder were published in the 1990s. Interventions included insurance (25%), medication (38%), and health services (38%). CONCLUSIONS: Healthcare CVM studies in Sub-Sahara Africa are limited despite the introduction of Bamako Initiative. The predominance of the bidding game elicitation technique in evaluated studies may be a reflection of the actual African market conditions. There is continuing debate as to which is the most appropriate CVM for healthcare studies conducted in Africa This debate will continue until these methods are compared to actual markets. CVM studies may start to engage the political market as Africa moves towards universal health coverage.
PRM6

DEVELOPMENT OF AN INCREMENTAL COST-EFFECTIVENESS RATIO WITH SOME EQUITY IMPLICATION
Wang JD 1 , Hung MC 2 1 National Cheng Kung University College of Medicine, Tainan, Taiwan, 2 National Taiwan University, Taipei, Taiwan OBJECTIVES: The conventional ICER (incremental cost-effectiveness ratio), which quantifies how many dollars are spent per QALY (quality-adjusted life year) gained from a specific health technology, has been criticized as unfair to the aged and/or physically challenged. METHODS: By taking the position that every life is equally important and every citizen is entitled to access health care services for the entire duration of his/her life expectancy, we replace the denominator of the conventional ICER, with the proportion of life, which is the quality-adjusted life expectancy (QALE) gained from the specific health technology divided by the QALE of the corresponding age-and gender-matched general population. The numerator is converted to the additional monetary cost spent over a lifetime after adjustment for annual discount rate. The new indicator quantifies how many dollars are spent to save the life of a person with a specific illness, and how much can be saved by preventing the occurrence of that illness. RESULTS: We have applied the estimation method to compare patients with liver cancer; breast cancer, acquired immunodeficiency syndrome, maintenance hemodialysis and peritoneal dialysis, and prolonged mechanical ventilation. CONCLUSIONS: Because the proposed indicator accounts for a fair opportunity for the aged and disabled more than the conventional ICER does, we recommend that this indicator be applied in future deliberations of health care resource allocation. Iaconi A, Khalidi N, Olanrewaju O, Balkrishnan R University of Michigan, Ann Arbor, MI, USA OBJECTIVES: Determination of the price of a drug starts in its early developmental stages and it is driven by various competitive health market forces. The purpose of the study is to explore associations between pharmaceutical pricing and the value of drugs. METHODS: Based on FDA indications we have identified three different drug categories: life saving drugs, drugs that are not life saving but save lives overtime, and drugs that only treat disease symptoms and affect QOL. We have investigated our theory of an association between drug intended outcomes and the price tag placed on a drug by performing a literature review of cost analyses for drugs selected in each category. The literature review included a combination of key words such as the name of the drug, cost-effectiveness, cost-utility, and QALY. We identified articles from the past 10 years published only in the English language. For each drug, studies reporting ICER/QALY values were selected. ICER/ QALY data were recorded and the values of the three categories were compared among each other and with the published acceptable QALY threshold value of US$64,000. RESULTS: For the life saving drugs group the highest ICER/QALY value is US$150,843 and lowest is €6,880, for the disease ameliorating drugs group €105,599 and US$544, and for the drugs treating disease symptoms and affecting QOL £154,831 and $US1,056 respectively. The majority of drugs in the first category were found to have ICER/ QALY values greater than the $64,000 value, while the majority of the drugs selected in the second and third categories were found to have ICER/ QALY values smaller than the $64,000 value. CONCLUSIONS: From our study we have found that drugs that are life saving are more likely to have ICER/QALY values greater than the threshold values compared to drugs that are disease ameliorating and that are designed to improve patients' QOL.
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